Glecaprevir/Pibrentasvir Demonstrates High SVR Rates in Patients with HCV Genotype 2, 4, 5, or 6 Infection without Cirrhosis Following an 8-Week Treatment Duration (SURVEYOR-II, Part 4)

Hassanein Tarek I.; Wyles David L.; Wang Stanley; Kwo Paul Y.; Shiffman Mitchell L.; Younes Ziad; Greenbloom Susan; Stedman Catherine A.; Sasadeusz Joe; Aguilar Humberto I.; Heo Jeong; Liu Ran; Ng Teresa; Lin Chih-Wei; Mensa Federico J.

首页> 外文期刊>Hepatology: Official Journal of the American Association for the Study of Liver Diseases >Glecaprevir/Pibrentasvir Demonstrates High SVR Rates in Patients with HCV Genotype 2, 4, 5, or 6 Infection without Cirrhosis Following an 8-Week Treatment Duration (SURVEYOR-II, Part 4)

【24h】

Glecaprevir/Pibrentasvir Demonstrates High SVR Rates in Patients with HCV Genotype 2, 4, 5, or 6 Infection without Cirrhosis Following an 8-Week Treatment Duration (SURVEYOR-II, Part 4)

机译：Glecaprevir / Pibrentasvir证明在经过8周的治疗后，具有HCV基因型2、4、5或6感染且无肝硬化的患者中SVR率较高（SURVEYOR-II，第4部分）

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

团队文献服务 >>

页面导航

著录项
引文网络
相似文献
相关主题

著录项

来源
《Hepatology: Official Journal of the American Association for the Study of Liver Diseases》 |2016年第6期|共1页
作者
Hassanein Tarek I.; Wyles David L.; Wang Stanley; Kwo Paul Y.; Shiffman Mitchell L.; Younes Ziad; Greenbloom Susan; Stedman Catherine A.; Sasadeusz Joe; Aguilar Humberto I.; Heo Jeong; Liu Ran; Ng Teresa; Lin Chih-Wei; Mensa Federico J.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类消化系及腹部疾病;
关键词

相似文献

外文文献
中文文献
专利

1. Glecaprevir/Pibrentasvir Demonstrates High SVR Rates in Patients with HCV Genotype 2, 4, 5, or 6 Infection without Cirrhosis Following an 8-Week Treatment Duration (SURVEYOR-II, Part 4) [J] . Hassanein Tarek I., Wyles David L., Wang Stanley, Hepatology: Official Journal of the American Association for the Study of Liver Diseases . 2016,第6期

机译：Glecaprevir / Pibrentasvir证明在经过8周的治疗后，具有HCV基因型2、4、5或6感染且无肝硬化的患者中SVR率较高（SURVEYOR-II，第4部分）
2. y Integrated analysis of 8-week glecaprevir/pibrentasvir in Japanese and overseas patients without cirrhosis and with hepatitis C virus genotype 1 or 2 infection [J] . Naganuma Atsushi, Chayama Kazuaki, Notsumata Kazuo, Journal of gastroenterology . 2019,第8期

机译：Y综合分析日语和海外患者8周Glecaprevir / Pibrentasvir的综合分析和肝炎病毒基因型1或2感染
3. Preliminary Efficacy and Safety of 8-Week Glecaprevir/Pibrentasvir in Patients with HCV Genotype 1-6 Infection and Compensated Cirrhosis: The Expedition-8 Study [J] . Brown Robert S. Jr., Hezode Christophe, Wang Stanley, Hepatology: Official Journal of the American Association for the Study of Liver Diseases . 2018,第6期

机译：HCV基因型患者8周Glecaprevir / Pibrentasvir的初步疗效和安全性1-6感染和补偿肝硬化：Expedition-8研究
4. Patients with HCV/HIV Co-infection Achieving a Sustained Virological Response Following HCV Treatment with Peginterferon alfa-2a (PEGASYS) plus Ribavirin (COPEGUS) have Improved Health Related Quality of Life [C] . D.T. Dieterich, M. Rodriguez Torres, J.K. Rockstroh International AIDS Conference . 2004

机译：HCV / HIV的患者在用Peginterferon Alfa-2a（Pegasys）加上利巴韦林（Copegegs）后HCV治疗后实现持续的病毒学反应，具有改善的健康相关的生活质量
5. Integrated analysis of 8-week glecaprevir/pibrentasvir in Japanese and overseas patients without cirrhosis and with hepatitis C virus genotype 1 or 2 infection [O] . Atsushi Naganuma, Kazuaki Chayama, Kazuo Notsumata, -1

机译：综合分析日本和海外无肝硬化并感染了1型或2型肝炎病毒的8周glecaprevir / pibrentasvir
6. IDDF2019-ABS-0210 Preliminary efficacy and safety of 8-week glecaprevir/pibrentasvir in patients with HCV genotype 1–6 infection and compensated cirrhosis: the EXPEDITION-8 study [O] . Robert S Brown, Christopher Hezode, Stanley Wang, 2019

机译：IDDF2019-ABS-0210 8周Glecaprevir / Pibrentasvir在HCV基因型1-6感染和补偿肝硬化患者中的初步疗效和安全性：Expedition-8研究

Glecaprevir/Pibrentasvir Demonstrates High SVR Rates in Patients with HCV Genotype 2, 4, 5, or 6 Infection without Cirrhosis Following an 8-Week Treatment Duration (SURVEYOR-II, Part 4)

著录项

引文网络

相似文献

相关主题

期刊订阅